Nova Leap Health (NLH) investor relations material

Executive summary

• Achieved record Q2 2026 revenue, income from operating activities, and Adjusted EBITDA, with both U.S. and Canadian segments contributing to growth.

• Revenue increased 17.1% year-over-year to $9.39 million in Q2 2026; trailing twelve-month revenue reached $33.6 million, the highest in company history.

• Adjusted EBITDA rose 65.2% year-over-year to $954,836, with margin exceeding 10% for the first time.

• Net income was $649,977 in Q2 2026, reversing a net loss of $484,008 in Q2 2025.

• Growth strategy included acquisition in Nova Scotia and new office opening in Massachusetts.

Financial highlights

• Q2 2026 revenue: $9,393,302, up 17.1% from Q2 2025.

• Q2 2026 Adjusted EBITDA: $954,836, up 65.2% from Q2 2025.

• Gross profit margin held steady at 40.3% in Q2 2026 versus 40.2% in Q2 2025.

• Income from operating activities: $754,667 in Q2 2026, up 115.4% year-over-year.

• Net income: $649,977 in Q2 2026 compared to net loss of $484,008 in Q2 2025.

Outlook and guidance

• Focus remains on deepening market presence, pursuing value-accretive acquisitions, and expanding operations.

• Continued investment in Florida and Texas for long-term growth opportunities.

• Management expects ongoing revenue and Adjusted EBITDA growth as scale and market density improve.

• Forward-looking statements caution that actual results may differ due to market and operational risks.